Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. The company supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). The company supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The company supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.
Follow-Up Questions
Qui est le CEO de Hikma Pharmaceuticals PLC ?
Mr. Riad Mishlawi est le Chief Executive Officer de Hikma Pharmaceuticals PLC, il a rejoint l'entreprise depuis 2011.
Quelle est la performance du prix de l'action HKMPY ?
Le prix actuel de HKMPY est de $47.47, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Hikma Pharmaceuticals PLC ?
Hikma Pharmaceuticals PLC appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de Hikma Pharmaceuticals PLC ?
La capitalisation boursière actuelle de Hikma Pharmaceuticals PLC est de $10.5B
Est-ce que Hikma Pharmaceuticals PLC est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 15 analystes ont établi des notations d'analystes pour Hikma Pharmaceuticals PLC, y compris 6 achat fort, 10 achat, 4 maintien, 0 vente et 6 vente forte